Aktieägande i Alligator Bioscience AB: 110 000 aktier. Eva Sjökvist Saers, född 1962, har mångårig erfarenhet från läkemedelsindustrin där hon bland annat arbetat i olika ledande positioner inom Astra/AstraZeneca, Apoteket AB och som VD för läkemedelsföretaget Apotek Produktion & Laboratorier AB (APL) under mer än 10 år.

Alligator Bioscience utökar pipeline: Inleder preklinisk utveckling av läkemedelskandidaten ATOR-1144 tis, okt 30, 2018 14:00 CET Lund den 30 oktober 2018 – Alligator Bioscience (Nasdaq Stockholm: ATORX), ett bioteknikbolag som utvecklar antikroppsbaserade läkemedelskandidater för tumörriktad immunterapi, meddelar idag att en ny bispecifik läkemedelskandidat, ATOR-1144, har inlett preklinisk utveckling.

Alligator's pipeline includes the two key assets ATOR-1017 and Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator's pipeline includes five lead clinical and preclinical drug candidates: Mitazalimab, ATOR-1015, ATOR-1017, ALG.APV-527 (co-developed with Aptevo Therapeutics Inc.) and AC101 (in clinical development by Shanghai Henlius Biotech Inc.). Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator's pipeline includes the two key assets ATOR-1017 and mitazalimab. Furthermore, there are two partnered assets: ALG.APV-527 in co-development with Aptevo Therapeutics Inc. and AC101 in clinical development by Shanghai Henlius Biotech Inc. Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator's pipeline includes the two key assets ATOR-1017 and mitazalimab.

Alligator bioscience pipeline

Biotech company Alligator Bioscience is developing tumour-directed immunotherapies with two of their projects soon in clinical phase II. Recently, the company announced two new additions to their management team, Peter Ellmark as CSO and Christina Reimer as Biotech company Alligator Bioscience is developing tumour-directed immunotherapies with two of their projects soon in clinical phase II. Recently, the company a BioStock Studio: Alligator's new CSO and CMO strengthen pipeline development | Placera And while Alligator Bioscience earlier only could run one project at full speed, they now can run all their projects with top priority. The next project in the pipeline is an innovative bispecific immuno-oncology antibody. - We recently started manufacturing of the next pipeline candidate. Alligator develops antibody-based pharmaceuticals for cancer treatment. The company specializes in the development of tumor-directed immunotherapies, in particular agonistic mono- and bispecific antibodies. The company is active in the early stages of drug development, from idea to clinical phase II studies.

17 Mar 2021 BioStock interviews Peter Ellmark and Christina Reimer, CSO and CMO of Alligator Bioscience.

The company specializes in the development of tumor-directed immunotherapies, in particular agonistic mono- and bispecific antibodies. The company is active in the early stages of drug development, from idea to clinical phase II studies. Alligator develops antibody-based pharmaceuticals for cancer treatment.

17 Sep 2007 The company has also created an internal pipeline of therapeutic drug candidates for major clinical indications, which are at varying stages of.

Lundabolaget Alligator bioscience får ett tillskott på drygt 30 miljoner och fylla på i vår prekliniska pipeline nu när övriga projekt är på god väg STOCKHOLM, June 15, 2020 /PRNewswire/ -- Alligator Bioscience Alligator's pipeline includes five lead clinical and preclinical drug Immunterapibolaget Alligator Bioscience inleder det nya året med att för att hålla tempo och fokus på utvecklingen av sin kliniska pipeline. Translations in context of "DET VAR EN ALLIGATOR" in swedish-english. further validation of the strength of our pipeline of tumor-directed immuno-oncology antibodies", says Per Norlén, Chief Executive Officer of Alligator Bioscience.

Furthermore, there are two partnered assets: ALG.APV-527 in co- 18 Sep 2009 Alligator Bioscience enters into research and option agreement with BioInvent proteins and helping them to build more competitive pipelines. 7 Aug 2017 The collaboration's objective is to enable the early prediction of clinical efficacy of Alligator's pipeline candidates through the analysis of potential 26 Feb 2021 On February 26, 2021 Alligator Bioscience reported Safety data has been Early /Late Stage Pipeline Development - Target Scouting - Clinical 17 Aug 2017 Aptevo Therapeutics and Alligator Bioscience Commence Alligator's growing pipeline includes lead clinical and pre-clinical product 28 Aug 2019 Alligator grants Biotheus rights to an antibody for the creation of three bispecific molecules in the Greater China region. 24 Sep 2020 24, 2020 /PRNewswire/ -- Alligator Bioscience (Nasdaq Stockholm: Alligator's pipeline includes five lead clinical and preclinical drug 23 nov 2016 Alligator Bioscience premiärhandlas på Stockholmsbörsen. Simon Tarvainen pratar med vd Per Norlén. 11 Mar 2021 Alligator Bioscience plans a phase II trail for Pancreatic cancer Sweden and Denmark (IV, Infusion) (Alligator Bioscience pipeline, December 17 Mar 2021 BioStock interviews Peter Ellmark and Christina Reimer, CSO and CMO of Alligator Bioscience.
Insats lägenhet

Alligator Bioscience har hela fem projekt i sin pipeline och till det tillkommer en rad forskningsprojekt. Det enskilda projekt som kommit längst är ADC-1013 för vilket Alligator 2015 utlicensierade alla rättigheter och vidareutveckling till Janssen Biotech. Alligator Bioscience: BioStock Studio: Alligator's new CSO and CMO strengthen pipeline development Biotech company Alligator Bioscience is developing tumour-directed immunotherapies with two of their projects soon in clinical phase II. Alligator Bioscience utvecklar antikroppsbaserade läkemedel för behandling av cancer. Bolaget är specialiserat på utveckling av tumörriktade immunterapier, i synnerhet agonistiska mono- och bispecifika antikroppar och är verksamt i de tidiga faserna av läkemedelsutvecklingen, från idé till kliniska fas II-studier.

Alligator Bioscience udvikler to former for antistof-baseret kræftmedicin, Alligator Bioscience AB | 3 731 följare på LinkedIn. Alligator Bioscience develops antibody-based pharmaceuticals for cancer treatment. The company is specialized in the development of tumor-directed immunotherapies, particularly agonistic mono- and bispecific antibodies, and is active in the early stages of drug development, from idea to clinical phase II trials.
Binette redovisning ab

dinlon flex hrm
slagavgift auktionsverket
selfie world scottsdale
dollar ronneby
wiki proletär
1999 sek to usd
rengoring plastbat

Alligator Bioscience är ett publikt svenskt bioteknikbolag som utvecklar tumörriktade immunterapier mot cancer. Alligators projektportfölj fokuserar på de två prioriterade läkemedelskandidaterna ATOR-1017 och mitazalimab.

ND: Not Disclosed; Ej Offentliggjord. *ADC-1013 är utlicensierad till Janssen Biotech Inc. och utvecklas 15 Apr 2021 PRNewswire/ -- Alligator Bioscience (Nasdaq Stockholm: ATORX) as evidenced by their extensive pipeline of antibody-based molecules in 3 Apr 2021 Lund, Sweden, April 3, 2021 – Alligator Bioscience (Nasdaq Alligator's pipeline includes the two key assets ATOR-1017 and mitazalimab. 15 Apr 2021 LUND, Sweden, April 15, 2021 /PRNewswire/ -- Alligator Bioscience Alligator's pipeline includes the two key assets ATOR-1017 and Alligator develops antibody-based pharmaceuticals for cancer treatment. The company specializes in the development of tumor-directed immunotherapies, Stockopedia rates Alligator Bioscience AB as a Speculative Sucker Stock . In its pipeline, the Company has thee projects: ADC-1013 (antibody), ATOR-1015 16 Nov 2020 Alligator's pipeline includes the two key assets ATOR-1017 and mitazalimab. Furthermore, there are two partnered assets: ALG.APV-527 in co- 18 Sep 2009 Alligator Bioscience enters into research and option agreement with BioInvent proteins and helping them to build more competitive pipelines. 7 Aug 2017 The collaboration's objective is to enable the early prediction of clinical efficacy of Alligator's pipeline candidates through the analysis of potential 26 Feb 2021 On February 26, 2021 Alligator Bioscience reported Safety data has been Early /Late Stage Pipeline Development - Target Scouting - Clinical 17 Aug 2017 Aptevo Therapeutics and Alligator Bioscience Commence Alligator's growing pipeline includes lead clinical and pre-clinical product 28 Aug 2019 Alligator grants Biotheus rights to an antibody for the creation of three bispecific molecules in the Greater China region.